1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
Small Business Innovation Research and Small Business Technology Transfer (SBIR/STTR) - National Institute of General Medical Sciences (NIGMS) is sponsored by National Institute of General Medical Sciences (NIGMS) / National Institutes of Health (NIH).
NIGMS supports innovative SBIR/STTR projects that could benefit research communities related to its mission, focusing on basic research that increases understanding of biological processes. This includes technology development for biomedical research and multi-scale computational modeling, bioinformatics, and biostatistics.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: U.S. small businesses (500 or fewer employees) engaging in research and development activities with strong potential for commercialization. STTR requires a partnership with a non-profit research institution. Confirm the full requirements in the official notice before applying.
Small Business Innovation Research and Small Business Technology Transfer (SBIR/STTR) - National Institute of General Medical Sciences (NIGMS) is funded by National Institute of General Medical Sciences (NIGMS) / National Institutes of Health (NIH). Verify program details on the funder's official page before applying.
Yes — this listing is flagged as national in scope, so applicants across the U.S. may apply, subject to the sponsor's other eligibility criteria.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
Past winners and funding trends for this program
Limited Competition: Institutional Development Award (IDeA) for Clinical & Translational Research (CTR) (P30 - CT Optional) is sponsored by National Institute of General Medical Sciences (NIGMS) / National Institutes of Health (NIH). This grant aims to advance gene-based therapies for ultra-rare neurological and neuromuscular disorders. This initiative focuses on IND-enabling studies and supports the development of innovative therapeutics with proven biological rationale.
Focused Technology Research and Development (R01 Clinical Trial Not Allowed) is sponsored by National Institute of General Medical Sciences (NIGMS) / National Institutes of Health (NIH). This Notice of Funding Opportunity (NOFO) supports projects relevant to the NIGMS mission that focus solely on the development of technologies with the potential to enable the acquisition of biomedical knowledge. The project outcome is a working prototype of the technology.
R21 Exploratory Technology Development is sponsored by National Institute of General Medical Sciences (NIGMS) / National Institutes of Health (NIH). This program supports exploratory technology development projects relevant to the NIGMS mission. It is suitable for novel, high-risk projects, and preliminary data is not required. The project outcome is a proof of concept study.
PAR-27-056 replaces the long-running IDeA-CTR U54 cooperative agreement with a P30 center core grant and splits the program into Development and Network tracks. Posted August 19, 2026, with a first estimated due date of October 9. Here is what the mechanism swap actually changes for the 23 IDeA states and Puerto Rico.
Read articleThe memorandum of agreement was signed August 4 and 5, disclosed by House appropriators on September 3, and runs through 2036. It names no dollar figure. Here is what is actually established, what is still speculation, and what researchers holding or planning NIAID biodefense awards should do before September 30.
Read articlePAR-27-054 and PAR-27-055 replace COBRE's Phase 1-2-3 model with two tracks: a 15-year Development-Expansion-Sustainability path and a 10-year Expansion-Sustainability path. At $1.5 million per year in direct costs across 23 states and Puerto Rico, with new research cores prohibited in the final phase and eligibility capped at three active awards per institution, the track you claim is the most consequential choice in the application.
Read article